deltatrials
Recruiting PHASE2 INTERVENTIONAL 3-arm NCT04918186

Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer (IPROC)

An Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer

Sponsor: AstraZeneca

Conditions Ovarian Cancer
Interventions BA3011 BA3021 Durvalumab ENB003 Toripalimab
Updated 21 times since 2021 Last updated: Feb 10, 2026 Started: May 3, 2022 Primary completion: Jun 30, 2026 Completion: Dec 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Ovarian Cancer, this trial is actively recruiting participants. The trial is conducted by AstraZeneca and has accumulated 21 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Dec 2021 · 2 months · monthly snapshot~Dec 2021 – ~Apr 2022 · 4 months · monthly snapshot~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Sep 2022 · 4 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~May 2023 · 5 months · monthly snapshot~May 2023 – ~Jun 2023 · 31 days · monthly snapshot~Jun 2023 – ~Jul 2023 · 30 days · monthly snapshot~Jul 2023 – ~Sep 2023 · 2 months · monthly snapshot~Sep 2023 – ~Feb 2024 · 5 months · monthly snapshot~Feb 2024 – ~Mar 2024 · 29 days · monthly snapshot~Mar 2024 – ~Apr 2024 · 31 days · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Feb 2025 · 5 months · monthly snapshot~Feb 2025 – ~Oct 2025 · 8 months · monthly snapshot~Oct 2025 – ~Feb 2026 · 4 months · monthly snapshot~Feb 2026 – present · 5 months · monthly snapshot

Change History

21 versions recorded

  1. Feb 2026 — Present [monthly]

    Recruiting PHASE2

  2. Oct 2025 — Feb 2026 [monthly]

    Recruiting PHASE2

  3. Feb 2025 — Oct 2025 [monthly]

    Recruiting PHASE2

  4. Sep 2024 — Feb 2025 [monthly]

    Recruiting PHASE2

  5. Aug 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

▶ Show 16 earlier versions

  1. Jul 2024 — Aug 2024 [monthly]

    Recruiting PHASE2

  2. Apr 2024 — Jul 2024 [monthly]

    Recruiting PHASE2

  3. Mar 2024 — Apr 2024 [monthly]

    Recruiting PHASE2

  4. Feb 2024 — Mar 2024 [monthly]

    Recruiting PHASE2

  5. Sep 2023 — Feb 2024 [monthly]

    Recruiting PHASE2

  6. Jul 2023 — Sep 2023 [monthly]

    Recruiting PHASE2

  7. Jun 2023 — Jul 2023 [monthly]

    Recruiting PHASE2

  8. May 2023 — Jun 2023 [monthly]

    Recruiting PHASE2

  9. Dec 2022 — May 2023 [monthly]

    Recruiting PHASE2

  10. Nov 2022 — Dec 2022 [monthly]

    Recruiting PHASE2

  11. Sep 2022 — Nov 2022 [monthly]

    Recruiting PHASE2

  12. May 2022 — Sep 2022 [monthly]

    Recruiting PHASE2

  13. Apr 2022 — May 2022 [monthly]

    Recruiting PHASE2

  14. Dec 2021 — Apr 2022 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  15. Oct 2021 — Dec 2021 [monthly]

    Not Yet Recruiting PHASE2

  16. Sep 2021 — Oct 2021 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AstraZeneca
  • BioAtla, Inc.
  • Canadian Cancer Trials Group
  • Cancer Research Institute, New York City
Data source: Canadian Cancer Trials Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations